Alzheimer’s Research UK is a partner in a number of consortia and other research initiatives, both within the UK and internationally, which aim to accelerate progress in dementia research.
Here you can find more information about our partnerships, some of which provide experimental resources and bespoke funding calls.
- Brains for dementia research
- Join Dementia Research
- Lewy Body Society (UK)
- Chief Scientist Office (Scotland)
- Fight for Sight
- International Alzheimer’s disease Research Funder Consortium
- Dementia Consortium
- MCDN and BAND2
- Canadian Consortium on Neurodegeneration in Aging (CCNA)
- Coalition Against Major Diseases (CAMD)
Brains for dementia research
Brains for Dementia Research (BDR) is a joint initiative between Alzheimer’s Research UK and Alzheimer’s Society, in association with the Medical Research Council, which aims to provide high quality human brain tissue to the dementia research community You can find out more about BDR on Researcher Resources.
Join Dementia Research
The aim of Join Dementia Research, established by the National Institute of Health and Clinical Research with support from Alzheimer’s Research UK and Alzheimer’s Society, is to improve the timeliness of study recruitment for researchers, and provide a service to thousands of potential volunteers who want to be involved in research.
Lewy Body Society (UK)
Dr Jay Amin at the University of Southampton has been awarded £213,317.40 over three years to investigate the role of the immune system in dementia with Lewy bodies. This research was supported through an Alzheimer’s Research UK Clinical Research Fellowship with funding from the Lewy Body Society.
Fight for Sight
In partnership with the charitable organisation Fight for Sight, Alzheimer’s Research UK has co-committed £30,000 worth of funding for two, one-year long research projects. Both pioneering studies will investigate links between dementia and visual impairment.
International Alzheimer’s disease Research Funder Consortium
We co-lead this group of 20 dementia research funding bodies, alongside US-based National Institute for Ageing and the Alzheimer’s Association. The Consortium comes together to identify areas of common interest and gaps in knowledge and innovation, so that we can bridge these gaps through collaboration. This is an excellent opportunity for us to help shape the global research landscape and ensure that vital efforts aren’t being duplicated.
Clinical Research Fellowship
Designed for promising clinically qualified researchers who have delivered previous research projects with evidence of impactful outputs and have clear plans to establish their own research ‘niche’.
We are founding members of the Dementia Consortium, a £9.5million global partnership between Alzheimer’s Research UK, Evotec and the pharmaceutical companies, Abbvie, Astex, Eisai, Johnson & Johnson, Lilly and MSD. The aim is to close the gap between academic research and the pharmaceutical industry’s drug-discovery pipeline. Researchers looking to validate promising new targets and progress them into drug discovery research should direct applications to the Dementia Consortium.
MCDN and BAND2
We are partners, along with the Alzheimer’s Association and The Weston Brain Institute, in a global call for research into mechanisms of cellular death in neurodegeneration (MCDN, formerly known as MEND). Applications for this call have now closed.
We are also joint partners with the Alzheimer’s Association, the Michael J. Fox Foundation and the Weston Brain Institute, in a global funding call to stimulate analyses, development and standardisation of Biomarkers Across Neurodegenerative Diseases (BAND2). Applications for this call have now closed.
Canadian Consortium on Neurodegeneration in Aging (CCNA)
Alzheimer’s Research UK is one of the international partners of the CCNA, a large collaborative research initiative, which aims to prevent and mitigate the toll of dementia and related neurodegenerative diseases of ageing.
Coalition Against Major Diseases (CAMD)
The CAMD brings together funding bodies, pharmaceutical companies, academics and drug regulators with one core goal: to accelerate clinical trials for neurodegenerative diseases, starting with Alzheimer’s and Parkinson’s. Our involvement in this initiative will ensure that our interests as a funding body and our expertise in dementia drug discovery are represented in the international forum.
Neurodegeneration Medicines Acceleration Programme (Neuro-MAP)
We are partners along with several other charities and funding bodies in the Neurodegeneration Medicines Acceleration Programme (Neuro-MAP), a scheme which aims to identify promising drug projects no longer in development and help scientists to take them forward to the next stage.
The Alzheimer’s Research UK Research Network is a community of over 1,800 researchers across the UK, with each Network Centre providing pump priming, travel and equipment funding as well as local networking events.
We are supporting a range of international drug discovery opportunities for researchers looking to validate and progress targets for neurodegenerative diseases.